



51) International Patent Classification 7:		(11) International Publication Number: WO 00/30686	
A61K 39/395, C07K 16/00, 16/18, 16/28, 16/46, C12N 15/12, 15/13	A1	(43) International Publication Date: 2 June 2000 (02.06.00	
21) International Application Number: PCT/US99 22) International Filing Date: 23 November 1999 (23		BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA	
30) Priority Data: 60/109,607 23 November 1998 (23.11.98)		LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,	
71) Applicant (for all designated States except US): IDEC MACEUTICALS CORPORATION [US/US]; 1101 reyana Road, San Diego, CA 92121 (US).			
72) Inventor; and 75) Inventor/Applicant (for US only): COCCIA, Mar [US/US]; 1059 Wilbur Avenue, San Diego, CA (US).			
74) Agents: GESS, E., Joseph et al.; Burns, Doane, Swee Mathis, L.L.P., P.O. Box 1404, Alexandria, VA 2231 (US).			

(54) Title: TUMOR ANTIGEN-SPECIFIC ANTIBODY-GP39 CHIMERIC PROTEIN CONSTRUCTS

(57) Abstract

This invention relates generally to the production of antigen-binding chimeric proteins also comprising an immunoeffector binding domain. More specifically, the invention relates to chimeric proteins comprising a tumor antigen-specific antibody or antibody fragment fused to the CD40 ligand, gp39. Compositions comprising, genetic constructions for, methods of use, and methods for producing the chimeric proteins are also disclosed.